supp.fit

Epigallocatechin Gallate: study protocols

91 study groups say how much Epigallocatechin Gallate participants took a day. These are the doses the studies gave. They are not a recommendation.

Epigallocatechin Gallate: what the research found →

Dose per serving from products

167 products in our catalogue print how much Epigallocatechin Gallate a serving holds.

Most common: 100 mg to 250 mg, 37% of 167 products.

Dose per servingProducts
10 mg or less
7
10 mg to 25 mg
18
25 mg to 50 mg
26
50 mg to 100 mg
34
100 mg to 250 mg
61
250 mg to 500 mg
19
over 500 mg
2

Dose per serving from research

89 study groups in 55 studies say how much Epigallocatechin Gallate participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 250 mg to 500 mg and 500 mg to 1 g, 36% of 89 study groups each.

Daily doseStudy groups
100 mg or less
5
100 mg to 250 mg
12
250 mg to 500 mg
32
500 mg to 1 g
32
1 g to 2.5 g
8

Commonly used together

38 of 91 study groups took Epigallocatechin Gallate with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Green Tea Extract
16
Caffeine
8
Resveratrol
7

91 study groups

Study
Prevention of Acute Upper Respiratory Infections by Consumption of Catechins in Healthcare Workers: A Randomized, Placebo-Controlled Trial
2019 · high-catechin group · Healthy adult healthcare workers; mean age 43.2 years, 76.9% female across the analysis population.
60 mg12 weeks91
Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus
2015 · Poly E 600 mg BID · Adults aged 18 years or older with Barrett's esophagus, with or without low-grade dysplasia
1.2 g26 weeks20
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer
2012 · Poly E 400 mg EGCG dose level · Women aged 21–65 with a history of resected stage I–III hormone receptor-negative breast cancer and no evidence of disease
800 mg26 weeks16
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer
2012 · Poly E 600 mg EGCG dose level · Women aged 21–65 with a history of resected stage I–III hormone receptor-negative breast cancer and no evidence of disease
1.2 g26 weeks11
Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus
2015 · Poly E 400 mg BID · Adults aged 18 years or older with Barrett's esophagus, with or without low-grade dysplasia
800 mg26 weeks7
Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus
2015 · Poly E 200 mg BID · Adults aged 18 years or older with Barrett's esophagus, with or without low-grade dysplasia
400 mg26 weeks6
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer
2012 · Poly E 800 mg EGCG dose level · Women aged 21–65 with a history of resected stage I–III hormone receptor-negative breast cancer and no evidence of disease
1.6 g26 weeks3
Novel combined single dose anti-hepatitis C therapy: a pilot study
2021 · Arm 2: Catvira · Adults over 18 with chronic genotype 4 hepatitis C, non-cirrhotic and DAA-naïve; treatment-naïve or treatment-experienced
400 mg24 weeks40
Tea-induced improvement of endothelial function in humans: No role for epigallocatechin gallate (EGCG)
2017 · Isolated EGCG · Healthy men aged 20–50 years without chronic disease or stated cardiovascular risk factors
214 mg1 day50
Assessing the analgesic efficacy of oral epigallocatechin-3-gallate on epidural catheter analgesia in patients after surgical stabilisation of multiple rib fractures: a prospective double-blind, placebo-controlled clinical trial
2020 · EGCG group · Adults aged 18 or older with multiple rib fractures and intractable pain after surgical stabilisation of rib fractures
200 mg10 days49
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial
2016 · EGCG and cognitive training group · Adults aged 16–34 years with Down's syndrome
9 mg/kg1 year43
Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease
2007 · EGCG · Adults with coronary artery disease; age range and sex are not specified for the enrolled cohort.
300 mg2 weeks42
'Benifuuki' green tea containing o-methylated catechin reduces symptoms of Japanese cedar pollinosis: a randomized, double-blind, placebo-controlled trial
2014 · 'Benifuuki' green tea · Adults with Japanese cedar pollinosis
700 mL120 days26
Acute Epigallocatechin 3 Gallate (EGCG) Supplementation Delays Gastric Emptying in Healthy Women: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
2018 · EGCG group · Healthy young adult women, mean age 24.41 years; no stated disease or nutrient deficiency
752 mg1 day22
Epigallocatechin-3-gallate increases maximal oxygen uptake in adult humans
2010 · EGCG · Healthy adult males and females, mean age 26 ± 2 years
405 mg2 days19
Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial
2015 · EGCG · Adults with relapsing-remitting multiple sclerosis, expanded disability status scale score <4.5, receiving glatiramer acetate; 8 of 18 participants were men
600 mg12 weeks18
Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions
2003 · EGCG capsule · Patients with HPV-infected cervical lesions, including chronic cervicitis and mild, moderate or severe dysplasia; age and sex not specified
200 mg12 weeks10
A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis
2013 · 400 mg total EGCG daily · Patients with mild to moderate ulcerative colitis
400 mg8 weeks—
A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis
2013 · 800 mg total EGCG daily · Patients with mild to moderate ulcerative colitis
800 mg8 weeks—
Administration of a dietary supplement ( N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial
2009 · treatment group · Healthy overweight women and men; age not stated
100 mg60 days71
The combined effect of green tea and α-glucosyl hesperidin in preventing obesity: a randomized placebo-controlled clinical trial
2021 · GT-gH group · Healthy Japanese men and women aged 30–75 years with BMI 23–30 kg/m² and LDL cholesterol 100–140 mg/dL; not regular green tea consumers
146 mg12 weeks30
Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects
2014 · E+R · Healthy overweight women and men, mean age 35 years
282 mg3 days18
Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects
2014 · E+R+S · Healthy overweight women and men, mean age 35 years
282 mg3 days18
The effects of polyphenol supplementation on adipose tissue morphology and gene expression in overweight and obese humans
2018 · EGCG+RES · Overweight and obese men and premenopausal women; ages not specified
282 mg12 weeks11
Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans
1999 · green tea extract · 10 healthy men
270 mg1 day10
Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation
2005 · green tea-caffeine mixture · Overweight and moderately obese adults after body weight loss; matched for sex, age, BMI, height, body mass, and habitual caffeine intake
270 mg90 days—
Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men
2005 · 90 mg EGCG mixture · men; age and health condition not stated
270 mg1 day—
Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men
2005 · 200 mg EGCG mixture · men; age and health condition not stated
600 mg1 day—
Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men
2005 · 300 mg EGCG mixture · men; age and health condition not stated
900 mg1 day—
Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men
2005 · 400 mg EGCG mixture · men; age and health condition not stated
1.2 g1 day—
Green tea catechin plus caffeine supplementation to a high-protein diet has no additional effect on body weight maintenance after weight loss
2009 · adequate-protein diet plus green tea-caffeine mixture · Overweight and moderately obese adults, mean age 44 years, following weight loss
270 mg90 days—
Green tea catechin plus caffeine supplementation to a high-protein diet has no additional effect on body weight maintenance after weight loss
2009 · high-protein diet plus green tea-caffeine mixture · Overweight and moderately obese adults, mean age 44 years, following weight loss
270 mg90 days—
Does supplementation with green tea extract improve acne in post-adolescent women? A randomized, double-blind, and placebo-controlled clinical trial
2016 · decaffeinated green tea extract group · Women aged 25–45 years with moderate-to-severe post-adolescent acne
856 mg4 weeks—
Possible Reduction of Cardiac Risk after Supplementation with Epigallocatechin Gallate and Increase of Ketone Bodies in the Blood in Patients with Multiple Sclerosis. A Pilot Study
2020 · intervention group · Adults over 18 with multiple sclerosis, treated with glatiramer acetate and interferon beta, able to move without a wheelchair or walker
800 mg120 days—
A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- ɛ4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial (PENSA study)
2025 · MLI+EGCG, participants weighing 50 kg or less · Adults aged 60–80 with subjective cognitive decline who carried APOE-ε4 and had normal-range cognitive performance
300 mg1 year—
A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- ɛ4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial (PENSA study)
2025 · MLI+EGCG, participants weighing more than 50 kg · Adults aged 60–80 with subjective cognitive decline who carried APOE-ε4 and had normal-range cognitive performance
500 mg1 year—
Epigallocatechin gallate enhances sympathetic heart rate variability and decreases blood pressure in obese subjects: a randomized control trial
2024 · EGCG group · Thai adults over 18 years with obesity (BMI ≥25 kg/m²); men and women
300 mg8 weeks15
Improvement in insulin resistance and favourable changes in plasma inflammatory adipokines after weight loss associated with two months' consumption of a combination of bioactive food ingredients in overweight subjects
2013 · dietary supplement group · Healthy overweight men and women aged 25–45 years with BMI greater than 25 and less than 35 kg/m²
300 mg8 weeks50
A Randomized, Placebo-Controlled Study on the Safety and Efficacy of Daily Ingestion of Green Tea (Camellia sinensis L.) cv. "Yabukita" and "Sunrouge" on Eyestrain and Blood Pressure in Healthy Adults
2018 · Sunrouge group · Japanese adults aged 21–55 years with slightly elevated blood pressure
324 mg12 weeks39
A Randomized, Placebo-Controlled Study on the Safety and Efficacy of Daily Ingestion of Green Tea (Camellia sinensis L.) cv. "Yabukita" and "Sunrouge" on Eyestrain and Blood Pressure in Healthy Adults
2018 · Yabukita group · Japanese adults aged 21–55 years with slightly elevated blood pressure
322 mg12 weeks38
Epigallocatechin gallate (EGCG) (TEAVIGO) does not impair nonhaem-iron absorption in man
2005 · 150 mg EGCG · Healthy women with low iron stores
150 mg8 days30
Epigallocatechin gallate (EGCG) (TEAVIGO) does not impair nonhaem-iron absorption in man
2005 · 300 mg EGCG · Healthy women with low iron stores
300 mg8 days30
Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals
2005 · 400 mg dose group · healthy volunteers
400 mg1 day10
Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals
2005 · 800 mg dose group · healthy volunteers
800 mg1 day10
Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals
2005 · 1,200 mg dose group · healthy volunteers
1.2 g1 day10
A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers
2017 · low-dose Polyphenon E · Adults aged 18 years or older with a bladder tumor; men and women
800 mg4 weeks10
A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers
2017 · high-dose Polyphenon E · Adults aged 18 years or older with a bladder tumor; men and women
1.2 g4 weeks10
A single ascending dose study of epigallocatechin gallate in healthy volunteers
2003 · 50 mg EGCG group · healthy male volunteers
50 mg1 day8
A single ascending dose study of epigallocatechin gallate in healthy volunteers
2003 · 100 mg EGCG group · healthy male volunteers
100 mg1 day8
A single ascending dose study of epigallocatechin gallate in healthy volunteers
2003 · 200 mg EGCG group · healthy male volunteers
200 mg1 day8
A single ascending dose study of epigallocatechin gallate in healthy volunteers
2003 · 400 mg EGCG group · healthy male volunteers
400 mg1 day8
A single ascending dose study of epigallocatechin gallate in healthy volunteers
2003 · 800 mg EGCG group · healthy male volunteers
800 mg1 day8
A single ascending dose study of epigallocatechin gallate in healthy volunteers
2003 · 1600 mg EGCG group · healthy male volunteers
1.6 g1 day8
Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E
2001 · EGCG, 200 mg dose level · Healthy subjects; age and sex not specified
200 mg1 day5
Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E
2001 · EGCG, 400 mg dose level · Healthy subjects; age and sex not specified
400 mg1 day5
Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E
2001 · EGCG, 600 mg dose level · Healthy subjects; age and sex not specified
600 mg1 day5
Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E
2001 · EGCG, 800 mg dose level · Healthy subjects; age and sex not specified
800 mg1 day5
Dietary epigallocatechin 3-gallate supplement improves maternal and neonatal treatment outcome of gestational diabetes mellitus: a double-blind randomised controlled trial
2017 · EGCG study group · Pregnant women in their third trimester with gestational diabetes mellitus
500 mg—176
Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation
2012 · 135 mg EGCG · Healthy adults
135 mg1 day27
Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation
2012 · 270 mg EGCG · Healthy adults
270 mg1 day27
The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial
2016 · GTP group · Adults aged 18 years or older with type 1 or type 2 diabetes and persistent micro- or macroalbuminuria despite ACE inhibitor and/or ARB treatment
800 mg12 weeks24
Acute Epigallocatechin-3-Gallate Supplementation Alters Postprandial Lipids after a Fast-Food Meal in Healthy Young Women: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
2020 · EGCG group · Healthy women aged 18–25 years
800 mg1 day14
Effects of Timing of Acute and Consecutive Catechin Ingestion on Postprandial Glucose Metabolism in Mice and Humans
2020 · morning-green tea (MGT) · Healthy young adults; 18–? years; men and women, without diagnosed diabetes or dyslipidaemia
135 mg5 days10
Effects of Timing of Acute and Consecutive Catechin Ingestion on Postprandial Glucose Metabolism in Mice and Humans
2020 · evening-green tea (EGT) · Healthy young adults; 18–? years; men and women, without diagnosed diabetes or dyslipidaemia
135 mg5 days9
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals
2003 · 800 mg EGCG once/day · Healthy individuals with Fitzpatrick skin type II or III
800 mg4 weeks8
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals
2003 · 400 mg EGCG twice/day · Healthy individuals with Fitzpatrick skin type II or III
800 mg4 weeks8
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals
2003 · 800 mg EGCG as Polyphenon E once/day · Healthy individuals with Fitzpatrick skin type II or III
800 mg4 weeks8
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals
2003 · 400 mg EGCG as Polyphenon E twice/day · Healthy individuals with Fitzpatrick skin type II or III
800 mg4 weeks8
The polyphenol epigallocatechin gallate lowers circulating catecholamine concentrations and alters lipid metabolism during graded exercise in man: a randomized cross-over study
2023 · EGCG trial · Apparently healthy men; mean age 22.3 years
1.45 g1 day8
Tracking CNS and systemic sources of oxidative stress during the course of chronic neuroinflammation
2015 · glatiramer acetate and EGCG · Adults with relapsing-remitting multiple sclerosis receiving glatiramer acetate; age range and sex not specified
600 mg—6
Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial
2009 · EGCG · Men aged 40–65 years with BMI >28 and <38, who were overweight or obese, non-diabetic, and without significant disease
800 mg8 weeks—
Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women
2023 · EGCG alone · Women aged 18–40 years, with or without uterine fibroids; no known liver disease or history of alcohol abuse
720 mg5 weeks—
Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women
2023 · EGCG + clomiphene citrate · Women aged 18–40 years, with or without uterine fibroids; no known liver disease or history of alcohol abuse
720 mg5 weeks—
Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women
2023 · EGCG + letrozole · Women aged 18–40 years, with or without uterine fibroids; no known liver disease or history of alcohol abuse
720 mg5 weeks—
Effects of green tea supplementation on elements, total antioxidants, lipids, and glucose values in the serum of obese patients
2012 · GTE group · Adults aged 30–60 with obesity (BMI ≥30 kg/m²), 23 men and 23 women across the study
208 mg90 days23
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene
2025 · EGCG · Non-pregnant, non-lactating women aged 18–40 years, with or without uterine fibroids
720 mg30 days12
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene
2025 · EGCG + letrozole · Non-pregnant, non-lactating women aged 18–40 years, with or without uterine fibroids
720 mg30 days10
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene
2025 · EGCG + clomiphene · Non-pregnant, non-lactating women aged 18–40 years, with or without uterine fibroids
720 mg30 days8
The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial
2015 · GTE · Postmenopausal women aged 50–70 years with high mammographic density and no history of cancer or proliferative breast disease
843 mg1 year538
Effects of green tea catechin extract on serum lipids in postmenopausal women: a randomized, placebo-controlled clinical trial
2016 · GTE · Healthy postmenopausal women
843 mg1 year538
Green tea extract supplementation does not modify plasma concentration of F(2)-isoprostanes in women who are postmenopause: Findings from a randomized controlled trial
2023 · GTE intervention · Postmenopausal women aged 50–70 years, generally healthy and at increased breast-cancer risk due to high breast tissue density
843 mg1 year131
Green tea extract and catechol-O-methyltransferase genotype modify the post-prandial serum insulin response in a randomised trial of overweight and obese post-menopausal women
2017 · GTE · Postmenopausal women aged 50–70 years who were overweight or obese and had dense breast tissue
843 mg1 year30
Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity
2024 · EGCG+RES · Healthy men and women aged 20–50 years with overweight or obesity and normal glucose tolerance
282 mg12 weeks20
Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers
2021 · GTE phase · Healthy Japanese adults aged 21–29 years; 7 men and 5 women enrolled
300 mg1 day10
Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome
2011 · green tea · Adults with obesity and metabolic syndrome; age and sex not further specified
440 mg8 weeks—
Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome
2011 · green tea extracts · Adults with obesity and metabolic syndrome; age and sex not further specified
460 mg8 weeks—
Effect of mixed flavonoids, n-3 fatty acids, and vitamin C on oxidative stress and antioxidant capacity before and after intense cycling
2011 · QFO · Athletes; age and sex not specified
30 mg17 days—
Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial
2016 · EGCG+RES · Overweight and obese adults; 18 men among 38 participants, mean age 38 ± 2 years; insulin resistance is discussed, but is not specified as an inclusion criterion
282 mg12 weeks—
Gut microbiota composition in relation to the metabolic response to 12-week combined polyphenol supplementation in overweight men and women
2017 · EGCG+RES · Overweight and obese men and women; mean age 37.8 years; 18 men and 19 women enrolled
282 mg12 weeks—
Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers
2018 · Green tea extract (GTE) · Healthy volunteers; age and sex not reported
150 mg1 day—
Global testing of shifts in metabolic phenotype
2018 · PP intervention · Overweight and obese adults
282 mg12 weeks—